questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact on patients with relapsed or refractory Mantle Cell Lymphoma of NICE’s draft decision not to recommend brexucabtagene autoleucel (Tecartus) for N
answerText: The National Institute for Health and Care Excellence (NICE) is currently re-evaluating brexucabtagene autoleucel to determine whether it can be recommended for routine National Health Service funding following a period of managed access through the Cance...
heading: Blood Cancer: Medical Treatments